Brief: Petros Pharmaceuticals Establishes Steering Committee To Expand Into Non-Rx Status For Stendra
04/02/2021 13:37
Feb 4 (Reuters) - Petros Pharmaceuticals Inc PTPI.O :
* PETROS PHARMACEUTICALS ESTABLISHES STEERING COMMITTEE TO
EXPAND
INTO NON-RX STATUS FOR STENDRA® (AVANAFIL)
Source text for Eikon: ID:nPn1Rh4Yma
Further company coverage: PTPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Petros Pharmaceuticals
See all newsBrief: Petros Pharmaceuticals Assigns All Assets To Pt Liquidation, For Benefit Of Creditors
Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions